Healthcare of Ontario Pension Plan Trust Fund Acquires Shares of 92,000 Astera Labs, Inc. $ALAB

Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB) in the 1st quarter, Holdings Channel reports. The fund bought 92,000 shares of the company’s stock, valued at approximately $10,083,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ALAB. Reflection Asset Management acquired a new stake in Astera Labs during the 4th quarter worth approximately $25,000. Smartleaf Asset Management LLC lifted its holdings in shares of Astera Labs by 422.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 188 shares of the company’s stock worth $32,000 after purchasing an additional 152 shares during the period. Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new position in Astera Labs in the 4th quarter valued at $33,000. Whipplewood Advisors LLC raised its position in Astera Labs by 15,950.0% during the 1st quarter. Whipplewood Advisors LLC now owns 321 shares of the company’s stock worth $35,000 after buying an additional 319 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Astera Labs by 78.9% in the 4th quarter. Assetmark Inc. now owns 229 shares of the company’s stock worth $38,000 after acquiring an additional 101 shares during the period. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Insider Activity

In other news, Director Jack R. Lazar sold 10,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $355.17, for a total value of $3,551,700.00. Following the completion of the transaction, the director directly owned 75,688 shares of the company’s stock, valued at $26,882,106.96. The trade was a 11.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bethany Mayer sold 686 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $395.04, for a total value of $270,997.44. Following the completion of the sale, the director owned 5,550 shares in the company, valued at $2,192,472. This represents a 11.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,676,845 shares of company stock worth $444,928,806 in the last quarter. 10.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ALAB has been the topic of a number of recent analyst reports. Bank of America boosted their price target on shares of Astera Labs from $240.00 to $450.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 23rd. Needham & Company LLC lifted their price target on Astera Labs from $220.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Evercore reiterated an “outperform” rating and issued a $297.00 price objective on shares of Astera Labs in a research report on Tuesday, May 19th. Northland Securities lowered shares of Astera Labs from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Finally, Morgan Stanley increased their price target on shares of Astera Labs from $210.00 to $240.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Twelve investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $282.00.

Astera Labs Price Performance

Shares of NASDAQ ALAB opened at $260.23 on Wednesday. Astera Labs, Inc. has a 12-month low of $97.89 and a 12-month high of $499.48. The company has a market capitalization of $44.61 billion, a PE ratio of 175.83, a price-to-earnings-growth ratio of 3.27 and a beta of 3.66. The firm’s 50-day moving average is $360.60 and its two-hundred day moving average is $227.59.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.07. Astera Labs had a net margin of 26.72% and a return on equity of 18.49%. The business had revenue of $308.36 million during the quarter, compared to analysts’ expectations of $292.19 million. During the same period last year, the company posted $0.33 EPS. The company’s revenue was up 93.5% on a year-over-year basis. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. On average, analysts forecast that Astera Labs, Inc. will post 1.86 EPS for the current fiscal year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.